Evaluation of Safety of ZyComb® In Patients With Common Cold - ZIP 3000 (XY-005-IM)

Official Title: “A Non-Interventional, Non-Controlled, Post-Marketing Study to Obtain Knowledge of the Safety of ZyComb® (Xylometazoline Hydrochloride 0.5 mg/mL and Ipratropium Bromide 0.6 mg/mL) for Symptoms of Common Cold in a Real-Life OTC Setting”

The objectives of the study are to obtain knowledge about the safety in use, the patients' general impression of the treatment and the pattern of use of ZyComb® in an over-the-counter (OTC) setting.

Intervention(s) in this Clinical Trial

• Drug: xylometazoline hydrochloride and ipratropium bromide (ZyComb)
  • Common cold in a real-life OTC setting

Inclusion Criteria:

• For inclusion the patient must buy ZyComb® nasal spray with the intention to start using it either the same or the next day.

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Nycomed Industry

Overall Clinical Trial Officials and Contacts

Nycomed Clinical Trial Operations Study Chair Headquaters  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00480194

Study ID Number: XY-005-IM

ClinicalTrials.gov Identifier: NCT00480194

Health Authority: Sweden: Medical Products Agency